For
UK
audiences
The essential guide to product selection
The essential guide to product selection
Aminosalicylate
Acute attacks of mild-to-moderate and severe UC and active CD in adults; maintenance of remission of UC in adults
Asthma; acute porphyrias; glucose-6-phosphate dehydrogenase (G6PD) deficiency; severe renal impairment. Risk of haematological and hepatic toxicity (usually in first 3-6 months); treatment should be discontinued. | Potential side effects: Joint pain; cough; diarrhoea; dizziness; fever; gastrointestinal discomfort; headache; low white blood cell count; nausea; skin reactions; vomiting; insomnia; tinnitus; urine abnormalities; mouth ulcers; altered taste
Oral tablet/suspension; suppository
Dose: Oral 1–2.4g four times daily in acute attacks until remission, then 500mg four times daily. Rectal 0.5–1g twice daily, alone or in conjection with oral therapy
500mg suppository (10), £3.30; generic: 500mg tablets (112), £55.59; 500mg gastro-resistant tablets (112), £62.66; 250g/5ml oral suspension (500), £125.00; 500mg suppositories (10), £3.30